

## Genome-wide Approach vs Candidate Gene Approach in Personalizing Warfarin Therapy

Sang-Seop Lee<sup>1</sup>, Ho-Sook Kim<sup>1</sup>, Minkyung Oh<sup>2</sup>, Yin-Jin Jang<sup>1</sup>, Kyoung-Woo Je<sup>1</sup>, Eun-Young Kim<sup>1,2</sup>, Mushiroda Taisei<sup>3</sup>, Ji-Hong Shon<sup>1,2</sup>, Jae-Gook Shin<sup>1,2</sup>

<sup>1</sup>Department of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine,

<sup>2</sup>Department of Clinical Pharmacology, Pusan Paik Hospital, Busan, Korea,

<sup>3</sup>Laboratory for Pharmacogenetics, SNP Research Center, RIKEN, Tokyo, Japan

---

Warfarin is a anticoagulant used for the prophylaxis of thrombosis and embolism. Warfarin therapy shows a wide inter-individual variation among patients in its required dosage. This variation is in part due to the well known environmental or demographic factors including age, weight, co-administered drugs, etc. In an effort to assess genetic contribution to individual variation to warfarin therapy, a number of candidate gene approaches have been carried out and several candidate genes have been identified. Genetic variations in warfarin metabolizing enzyme, cytochrome P450 2C9, and in Vitamin K epoxide reductase complex subunit 1 have been repeatedly associated with altered therapeutic dose of warfarin and are now regarded as valid genetic markers for personalized warfarin therapy. Genetic variations of these two enzymes help to explain more than 30% of the variability of warfarin dose. When genetic factors are combined with the demographic factors, the extent of predictability can be increased upto 65%. In order to discover the additional relevant genetic variations to affect warfarin therapy, two different approaches may be adopted according to the study design; genome-wide and candidate gene approaches. During last several years of candidate gene approaches have identified several additional genes including mEH, ApoE, GGCX, CALU, etc. but the results are not conclusive. One of the reasons for the controversial results of the candidate gene approach may be the fact that only limited number of genetic variants is investigated in this approach. To overcome this problem, genome-wide approach with the DNA arrays has been tested. In this presentation, two genetic approaches are introduced and compared with regard to variability of warfarin dose. And, a recent trend of global collaboration for warfarin pharmacogenomics will be addressed.

◆ Sang-Seop Lee, M.D., Ph.D. ◆

**Personal data**

Name Sang-Seop Lee  
Date of Birth March 22, 1969  
Address Department of Pharmacology and Pharmacogenomics research Center  
Inje University College of Medicine  
633-165 Gaegum-dong, jin-gu, Busan, 614-735 Korea  
(Tel:051-890-6748; Fax:051-893-1232)

**Education**

1993-1998 Department of Life Science, Korea Advanced Institute of Science and Technology (KAIST), Korea (PhD)  
Advisor: Dr. Yang Kyu-Hwan  
1991-1993 Department of Life Science, KAIST, Korea (MS)  
Advisor: Dr. Yang Kyu-Hwan  
1987-1991 Department of Life Science, KAIST, Korea (BS)  
Advisor: Dr. Lee Sung-Taek

**Dissertation Titles**

Ph. D. Thesis Regulation of Cytochrome P4501A1 Expression by Steroid Compounds  
M. S. Thesis Suppression of Cytochrome P450 Expression by Epidermal Growth Factor (EGF) in Primary Culture of Mouse Hepatocytes

**Professional and Research Experiences**

2008.2-Present Associate Professor at Inje University  
2004.3-2008.2 Assistant Professor at Inje University  
2002.4-2004.2 Fulltime lecturer at Inje University  
2000.5-2002.3 Visiting fellow in NINDS/NIH (미국립보건원)  
1998.9-2000.4 Postdoctoral researcher in KRIBB (생명공학연구원)  
1993.3-1998.8 Teaching and research assistant, Department of Life Science, KAIST

**Publications (2003-)**

Yea SS, Lee SS, Kim WY, Liu KH, Kim H, Shon JH, Cha IJ, Shin JG (2008). Genetic variations and haplotypes of UDP-glucuronosyltransferase 1A locus in a Korean population *Ther Drug Monit.* 30(1):23-34  
Kang HJ, Song IS, Lee SS, Yoo MA, Shin JG. (2008) Effects of dietary salt on the expression of drug transporters, cytochrome P4503a, and nuclear receptors in rats *Xenobiotica.* 38(2):147-55  
Kim EY, Cho DY, Shin HJ, Lee SS, Shon JH, Shin JG, Shin SG. (2008) Duplex pyrosequencing assay of the 388A>G and 521T>C SLCO1B1 polymorphisms in three Asian populations. *Clin Chim Acta.* 388(1-2):68-72  
Lee SJ, Lee SS, Jeong HE, Shon JH, Ryu JY, Sunwoo YE, Liu KH, Kang W, Park YJ, Shin CM, Shin JG (2007) The CYP3A4\*18 allele, the most frequent coding variant in asian populations, does not significantly affect the midazolam disposition in heterozygous individuals *Drug Metab Dispos.*

35(11):2095-101

- Lee SS, Lee SJ, Gwak J, Jung HJ, Thi-Le H, Song IS, Kim EY, Shin JG.(2007) Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations *Ther Drug Monit.* 29(4):455-9
- Jang YJ, Cha EY, Kim WY, Park SW, Shon JH, Lee SS, Shin JG.(2007) CYP2S1 gene polymorphisms in a Korean population *Ther Drug Monit.* 29(3):292-8
- Lee SS, Jeong HE, Yi JM, Jung HJ, Jang JE, Kim EY, Lee SJ, Shin JG.(2007) Identification and functional assessment of BCRP polymorphisms in a Korean population *Drug Metab Dispos.*35(4):623-32
- Kang HJ, Song IS, Shin HJ, Kim WY, Lee CH, Shim JC, Zhou HH, Lee SS, Shin JG.(2007) Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population *Drug Metab Dispos.*;35(4):667-75
- Gwak J, Cho M, Gong SJ, Won J, Kim DE, Kim EY, Lee SS, Kim M, Kim TK, Shin JG, Oh S.(2006) Protein-kinase-C-mediated beta-catenin phosphorylation negatively regulates the Wnt/beta-catenin pathway *J Cell Sci.* 15;119:4702-9
- Yea SS, Yang YI, Park SK, Jang WH, Lee SS, Seog DH, Park YH, Chun JH. (2006) Interleukin-4 C-590T polymorphism is associated with protection against nasal polyps in a Korean population *Am J Rhinol.* 20(5):550-3
- Kang HJ, Lee SS, Lee CH, Shim JC, Shin HJ, Liu KH, Yoo MA, Shin JG.(2006) Neurotoxic pyridinium metabolites of haloperidol are substrates of human organic cation transporters *Drug Metab Dispos.* 34(7):1145-51
- Liu KH, Kim MJ, Jeon BH, Shon JH, Cha IJ, Cho KH, Lee SS, Shin JG.(2006) Inhibition of human cytochrome P450 isoforms and NADPH-CYP reductase in vitro by 15 herbal medicines, including *Epimedium herba* *J Clin Pharm Ther.* 31(1):83-91
- Kim H, Kang S, Kim H, Yoon YJ, Cha EY, Lee HS, Kim JH, Yea SS, Lee SS, Shin JG, Liu KH.(2006) In vitro metabolism of a new cardioprotective agent, KR-32570, in human liver microsomes *Rapid Commun Mass Spectrom.* 20(5):837-43
- Kim H, Yoon YJ, Kim H, Cha EY, Lee HS, Kim JH, Yi KY, Lee S, Cheon HG, Yoo SE, Lee SS, Shin JG, Liu KH.(2005) In vitro metabolism of a new cardioprotective agent, KR-33028 in the human liver microsomes and cryopreserved human hepatocytes *Arch Pharm Res.* ;28(11):1287-92
- Shon JH, Yoon YR, Hong WS, Nguyen PM, Lee SS, Choi YG, Cha IJ, Shin JG (2005) Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism *Clin Pharmacol Ther.* 78(2):191-201
- Lee SS, Kim SY, Kim WY, Thi-Le H, Yoon YR, Yea SS, Shin JG.(2005) MDR1 genetic polymorphisms and comparison of MDR1 haplotype profiles in Korean and Vietnamese populations *Ther Drug Monit.*27(4):531-5
- Lee SS, Kim KM, Thi-Le H, Yea SS, Cha IJ, Shin JG.(2005) Genetic polymorphism of CYP2C9 in a Vietnamese Kinh population *Ther Drug Monit.* 27(2):208-10
- SS. Lee, HE. Jeong, KH. Liu, JY. Ryu, T. Moon, CN. Yoon, SJ. Oh, CH. Yun, JG. Shin (2005) Identification of functional characterization of novel CYP2J2 variants: G312 variant causes loss of enzyme catalytic activity. *Pharmacogenetics and Genomics*, 15:105-113
- KH. Liu, YK. Lee, JY. DJ. Lee, WK. Kang, SS. Lee, YR. Yoon, JG. Shin (2004) Simple and Sensitive Assay of Torasemide in Human Plasma by High-Performance Liquid Chromatography Using a Monolithic Silica Column. *Chromatographia*, 60:639-643
- KH. Liu, YM. Lee, JH. Shon, MJ. Kim, SS. Lee, YR. Yoon, IJ. Cha, JG. Shin (2004) Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. *Xenobiotica*, 34:429-438

- KH. Liu, SS. Lee, YE. Sunwoo, W. Kang, KS. Lee, YR. Yoon, JG. Shin (2004) HPLC Assay of Zonisamide (1, 2-Benzisoxazole-3-methanesulfonamide) in Human Plasma Using a Solid-Phase Extraction Technique. *Chromatographia*, 59:497-500
- JY. Kim, CY. Choi, KJ. Lee, DW. Shin, KS. Jung, YC. Chung, SS. Lee, JG. Shin, HG. Jeong (2004) Induction of inducible nitric oxide synthas and poinlammatory cytokines expression by o,p'-DDT in macrophages. *Toxicol Lett*, 147:261-2
- G. Lee, M. Tanaka, KH. Park, SS. Lee, YM. Kim, ES. Jun, SH. Lee, M. Mourdian MM (2004) Casein Kinase II-mediated phosphorylation Regulates  $\alpha$ -Synuclein/Synphilin-1 Inteaction and Inclusion Boy Formaion. *J Biol Chem*, 279:6834-6839
- KA. Kim, MJ. Kim, JY. Park, JH. Shon, YR. Yoon, SS. Lee, KH. Liu, JH. Chun, MH. Hyun, JG. Shin (2003) Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. *Drug Metab Dispos*, 31:1227-1234
- SS. Lee, SH. Kwon, JS. Sung, MY. Han, YM. Park (2003) Cloning and characterization of the rat Hsf2 promoter: a critical role of proximal E-box element and USF protein in Hsf2 regulation in different compartments of the brain. *Biochim Biophys Acta*, 1625:52-63
- SS. Lee, YM. Kim, E. Junn, G. Lee, KH. Park, M. Tanaka, RD. Ronchetti, MM. Quezado, MM. Mouradian (2003) Cell cycle aberrations by  $\alpha$ -synuclein over-expression and cyclin B immunoreactivity in Lewy bodies. *Neurobiology of Aging*, 24:687-696